Barclays PLC Athira Pharma, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 1,014 shares of ATHA stock, worth $588. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,014

Previous 1,014 -0.0%

Holding current value

$588

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$0.42 - $3.43 $42,861 - $350,034	-102,051 Reduced 99.02%	1,014 $0
Q2 2024 Aug 14, 2024	SELL	$1.92 - $2.71 $54,913 - $77,508	-28,601 Reduced 21.72%	103,065 $273,000
Q1 2024 May 15, 2024	SELL	$2.24 - $4.15 $94,024 - $174,196	-41,975 Reduced 24.17%	131,666 $361,000
Q4 2023 Feb 15, 2024	SELL	$1.39 - $2.46 $364,458 - $645,012	-262,200 Reduced 60.16%	173,641 $422,000
Q3 2023 Nov 07, 2023	BUY	$1.9 - $3.16 $412,172 - $685,508	216,933 Added 99.1%	435,841 $880,000
Q2 2023 Aug 03, 2023	SELL	$2.36 - $3.59 $40,615 - $61,783	-17,210 Reduced 7.29%	218,908 $646,000
Q1 2023 May 04, 2023	BUY	$2.26 - $4.22 $63,345 - $118,282	28,029 Added 13.47%	236,118 $590,000
Q4 2022 Feb 13, 2023	BUY	$2.76 - $3.71 $114,045 - $153,300	41,321 Added 24.78%	208,089 $659,000
Q3 2022 Nov 03, 2022	BUY	$2.93 - $3.96 $317,702 - $429,386	108,431 Added 185.87%	166,768 $495,000
Q2 2022 Aug 12, 2022	SELL	$2.74 - $13.43 $7,619 - $37,348	-2,781 Reduced 4.55%	58,337 $177,000
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $547,617 - $825,704	61,118 New	61,118 $826,000

Others Institutions Holding ATHA

# of Institutions

Shares Held

16.9M

Call Options Held

112K

Put Options Held

68K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.9M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account